Chlorobenzoylaminoadamantane formulation for physical performance at high and low temperatures
Patent disclosure · 2019
- What the patent describes
- Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.
- Reported evidence
- The patent reports longer treadmill endurance with the Chlodantane formulation under heat and cold. In heat, the selected comparison was 56.23 ± 5.36 versus 27.69 ± 1.31 minutes in controls. Ladasten showed a heat signal at the higher tested exposure but no significant cold-endurance benefit.
Cold-exposure motor coordination · 24.0 (17.0–33.0) s with the formulation versus 11.5 (9.5–15.5) s in cold-exposed controls · Medians and quartiles; intact animals 127.0 (100.5–183.0) s · p=0.04 versus cold control
Reported patent results
Reported findings
The formulation increased rod-retention time after cold stress but did not restore the intact-animal value.
Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.
Population or model Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cold-exposure motor coordination | 24.0 (17.0–33.0) s with the formulation versus 11.5 (9.5–15.5) s in cold-exposed controls | Medians and quartiles; intact animals 127.0 (100.5–183.0) s · p=0.04 versus cold control |
| Sydnocarb comparator | 6.5 (5.0–9.0) s versus 11.5 (9.5–15.5) s cold control | Worse retention in this test; not general clinical inferiority · p=0.04 |
These findings concern a specific formulation and mouse model. They do not establish human occupational performance or protection under dangerous temperature exposure.
Source for these results ↗ · Reviewed 2026-11-06
Patent claims and provenance
Use. Later Chlodantane use claims; Bromantane served as a comparator.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2704126C2 ↗ · 2019-10-24
- Earliest priority / filing
- 2016-11-28 / 2016-11-28
- Original applicant / assignee
- Российская Федерация, от имени которой выступает Министерство обороны Российской Федерации
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 62557483 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical composition based on chlorobenzoylaminoadamantane, which increases physical performance in high and low temperatures
Inventors: Сергей Борисович Середенин; Григорий Георгиевич Незнамов; Валерий Гаврилович Барчуков; Борис Михайлович Пятин; Нина Ивановна Авдюнина; Любовь Николаевна Грушевская; Надежда Михайловна Зайцева; Константин Викторович Алексеев; Евгения Викторовна Блынская; Анна Сергеевна Михеева; Людмила Михайловна Гаевая; Мария Сергеевна Сергеева; Сергей Александрович Крыжановский; Иосиф Борисович Цорин; Валерий Николаевич Столярук; Марина Борисовна Вититнова.
Study limitations and source details
Study limitations
- Patent-reported animal results are not an independently replicated clinical trial or evidence of safe heat/cold exposure.
- The response was non-linear; formulation-specific effects cannot be assigned to every Chlodantane product.
- The groups were small, and the source gives conflicting comparison-group sizes.
Source details
Patent
Selected source passages checked; complete methods and risk of bias not appraised.
Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.
Sources checked
Citation
Author unconfirmed. Chlorobenzoylaminoadamantane formulation for physical performance at high and low temperatures RU2704126C2; filed 28 November 2016
Related compounds
Chlodantane
N-(adamantan-2-yl)-4-chlorobenzamide (ADK-910), an experimental small molecule with an adamantane cage joined to a chlorobenzamide. Russian studies examined temperature stress and physical workload.
Bromantane
A synthetic adamantane drug, also called Ladasten, studied in Russian fatigue and stress research.
Bemitil
A synthetic benzimidazole derivative also called bemethyl or Metaprot. Soviet and Russian researchers studied it as an actoprotector, a drug intended to preserve physical work capacity under stress.